// App-Quantinova.ai

: INITIAL SAFETY AND EFFICACY OF LAROTRECTINIB IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): DATA FROM AN EXPANDED ACCESS PROGRAM

Researchers

Presenter

  • Denis Schewe

Principal Investigators

  • Gunnar Cario

  • Valentina Nardi

  • Nora Ku

  • Michael Cox

  • Hanno Hock

Medical Centers

  • University Hospital Schleswig-Holstein, Lubeck, Germany

  • Massachusetts General Hospital, Boston, MA, United States

  • Loxo Oncology, Inc, a wholly owned subsidiary of Eli Lilly and Company,South San Francisco,United States

Locations

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Neurotrophic tropomyosin receptor kinase

  • Cerebrospinal fluid

Drug/Treatment

  • Larotrectinib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • NCT03025360

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved